FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379051662> ?p ?o ?g. }

• W4379051662 endingPage "126" @default.
• W4379051662 startingPage "122" @default.
• W4379051662 abstract "Improving exercise tolerance is indisputably beneficial for long-term survival in patients treated with percutaneous coronary intervention (PCI). Although previous studies suggested that Yangxinshi tablets effectively improve exercise tolerance in patients with coronary heart disease, the evidence is limited due to the lack of high-quality randomized trials. The Effects of Yangxinshi Tablets on Exercise Tolerance Compared with Trimetazidine in Patients after PCI (HEARTRIP) trial is a multicenter, double-blind, double-dummy, active drug-controlled, randomized trial designed to test if the effects of Yangxinshi tablets on exercise tolerance are non-inferior to those of trimetazidine in patients undergoing PCI. A total of 668 patients who have undergone PCI for the first time and completed a cardiopulmonary exercise test (CPET) will be enrolled and randomly assigned, in a 1:1 ratio, to receive Yangxinshi tablets (3 tablets, 3 times/d) plus trimetazidine-placebo or trimetazidine (20 mg, 3 times/d) plus Yangxinshi-placebo for 24 weeks. The primary endpoint is metabolic equivalent of tasks (METs) measured by CPET at 24 weeks after randomization. The secondary endpoints include comprehensive CPET indicators, incidence of major adverse cardiac and cerebrovascular events, and depression (Patient Health Questionnaire-9), anxiety (Generalized Anxiety Disorder-7), and quality of life (Seattle Angina Questionnaire) scores. This study will appraise current clinical evidence on the beneficial effect of Yangxinshi tablets on improving exercise tolerance after PCI and may substantiate their use as an effective pharmacological option for cardiac rehabilitation patients. The HEARTRIP study protocol received approval from the ethics committee of the General Hospital of Northern Theater Command (Shenyang, China). The procedures set out in this protocol are in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The results will be published following the guidelines of the CONSORT statement in a peer-reviewed scientific journal (Trial registration number: NCT03809273)." @default.
• W4379051662 created "2023-06-02" @default.
• W4379051662 creator A5003056918 @default.
• W4379051662 creator A5016839056 @default.
• W4379051662 creator A5018940792 @default.
• W4379051662 creator A5034552631 @default.
• W4379051662 creator A5044544424 @default.
• W4379051662 creator A5060613106 @default.
• W4379051662 creator A5064842058 @default.
• W4379051662 creator A5065163990 @default.
• W4379051662 creator A5066163075 @default.
• W4379051662 creator A5092068254 @default.
• W4379051662 date "2023-06-01" @default.
• W4379051662 modified "2023-09-30" @default.
• W4379051662 title "Yangxinshi Tablets Versus Trimetazidine on Exercise Tolerance After Percutaneous Coronary Intervention: Rationale and Design of the Double-blind, Randomized HEARTRIP Trial" @default.
• W4379051662 cites W1553345686 @default.
• W4379051662 cites W1971474283 @default.
• W4379051662 cites W1996333864 @default.
• W4379051662 cites W2072849188 @default.
• W4379051662 cites W2130241430 @default.
• W4379051662 cites W2210526139 @default.
• W4379051662 cites W2751635652 @default.
• W4379051662 cites W2764234689 @default.
• W4379051662 cites W2765567574 @default.
• W4379051662 cites W2791453970 @default.
• W4379051662 cites W2916912835 @default.
• W4379051662 cites W3046426563 @default.
• W4379051662 cites W3113178943 @default.
• W4379051662 cites W3207625403 @default.
• W4379051662 cites W4223930638 @default.
• W4379051662 cites W4312660569 @default.
• W4379051662 doi "https://doi.org/10.1097/cd9.0000000000000094" @default.
• W4379051662 hasPublicationYear "2023" @default.
• W4379051662 type Work @default.
• W4379051662 citedByCount "0" @default.
• W4379051662 crossrefType "journal-article" @default.
• W4379051662 hasAuthorship W4379051662A5003056918 @default.
• W4379051662 hasAuthorship W4379051662A5016839056 @default.
• W4379051662 hasAuthorship W4379051662A5018940792 @default.
• W4379051662 hasAuthorship W4379051662A5034552631 @default.
• W4379051662 hasAuthorship W4379051662A5044544424 @default.
• W4379051662 hasAuthorship W4379051662A5060613106 @default.
• W4379051662 hasAuthorship W4379051662A5064842058 @default.
• W4379051662 hasAuthorship W4379051662A5065163990 @default.
• W4379051662 hasAuthorship W4379051662A5066163075 @default.
• W4379051662 hasAuthorship W4379051662A5092068254 @default.
• W4379051662 hasBestOaLocation W43790516621 @default.
• W4379051662 hasConcept C118552586 @default.
• W4379051662 hasConcept C126322002 @default.
• W4379051662 hasConcept C142724271 @default.
• W4379051662 hasConcept C159110408 @default.
• W4379051662 hasConcept C164705383 @default.
• W4379051662 hasConcept C168563851 @default.
• W4379051662 hasConcept C1862650 @default.
• W4379051662 hasConcept C197934379 @default.
• W4379051662 hasConcept C203092338 @default.
• W4379051662 hasConcept C204243189 @default.
• W4379051662 hasConcept C204787440 @default.
• W4379051662 hasConcept C27081682 @default.
• W4379051662 hasConcept C2777927741 @default.
• W4379051662 hasConcept C2778425758 @default.
• W4379051662 hasConcept C2779951463 @default.
• W4379051662 hasConcept C2780400711 @default.
• W4379051662 hasConcept C45393284 @default.
• W4379051662 hasConcept C500558357 @default.
• W4379051662 hasConcept C535046627 @default.
• W4379051662 hasConcept C558461103 @default.
• W4379051662 hasConcept C71924100 @default.
• W4379051662 hasConceptScore W4379051662C118552586 @default.
• W4379051662 hasConceptScore W4379051662C126322002 @default.
• W4379051662 hasConceptScore W4379051662C142724271 @default.
• W4379051662 hasConceptScore W4379051662C159110408 @default.
• W4379051662 hasConceptScore W4379051662C164705383 @default.
• W4379051662 hasConceptScore W4379051662C168563851 @default.
• W4379051662 hasConceptScore W4379051662C1862650 @default.
• W4379051662 hasConceptScore W4379051662C197934379 @default.
• W4379051662 hasConceptScore W4379051662C203092338 @default.
• W4379051662 hasConceptScore W4379051662C204243189 @default.
• W4379051662 hasConceptScore W4379051662C204787440 @default.
• W4379051662 hasConceptScore W4379051662C27081682 @default.
• W4379051662 hasConceptScore W4379051662C2777927741 @default.
• W4379051662 hasConceptScore W4379051662C2778425758 @default.
• W4379051662 hasConceptScore W4379051662C2779951463 @default.
• W4379051662 hasConceptScore W4379051662C2780400711 @default.
• W4379051662 hasConceptScore W4379051662C45393284 @default.
• W4379051662 hasConceptScore W4379051662C500558357 @default.
• W4379051662 hasConceptScore W4379051662C535046627 @default.
• W4379051662 hasConceptScore W4379051662C558461103 @default.
• W4379051662 hasConceptScore W4379051662C71924100 @default.
• W4379051662 hasIssue "2" @default.
• W4379051662 hasLocation W43790516621 @default.
• W4379051662 hasLocation W43790516622 @default.
• W4379051662 hasOpenAccess W4379051662 @default.
• W4379051662 hasPrimaryLocation W43790516621 @default.
• W4379051662 hasRelatedWork W193640619 @default.
• W4379051662 hasRelatedWork W2114392716 @default.
• W4379051662 hasRelatedWork W2127687375 @default.
• W4379051662 hasRelatedWork W2355614377 @default.

• next